Strategic partnerships Kezar Life Sciences is a clinical-stage biotech with collaboration history in Greater China and ongoing asset sales; exploring strategic partnerships or asset licensing opportunities could open new markets and funding paths while potentially preserving runway.

AI and analytics enabling The company operates with a cloud-based tech stack including AWS and Google Tag Manager, suggesting a modern infrastructure foundation; identify opportunities to offer data integration, cloud optimization, or analytics services to accelerate R&D data workflows.

Small molecule focus Kezar emphasizes first-in-class small-molecule therapies targeting intracellular regulators; prospect high-value collaboration or CRO/CMO services around preclinical-to-clinical transition, regulatory prep, and biomarker strategy for immune-mediated and oncologic programs.

Regulatory and AIH focus With programs in autoimmune hepatitis and regulatory updates around zetomipzomib, there is a potential for partnerships in regulatory consulting, trial design support, or companion diagnostic development as they advance clinical studies or respond to roadblocks.

Funding and runway Given modest revenue and a substantial funding stack, Kezar may be open to external collaborations, licensing deals, or joint ventures that provide non-dilutive or dilutive financing while accelerating their clinical assets.